(synthetic exendin-4): a potent ial therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 2004; 117: 77–88. 5. Holst JJ. Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diabetes Metab Res Rev 2002; 18: 430–441. 6. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia byexogenous glucagon-like peptide 1 (7–38 amide) in type 2(non-insulin-dependent) diabetic patients. Diabetologia 1993; 36: 741–744. 7. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulinsensitivitiy, and ß–cell function in type 2 diabetes: a parallel-group study. Lancet 2002; 359: 824–830. 8. G¨oke R, Fehmann HC, Linn T, et al. Exendin-4 is a high potency agonist and truncated exendin-(9–39)-amide an antagonist at Copyright 2004 John Wiley & Sons, Ltd. Diabetes Metab Res Rev 2004; 20: 411–417.